Product Information
OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-10-25 MG is a generic product labeled by Endo USA Inc., priced at $0.9895 per EA under NDC 49884079011. Its NADAC has been published 499 times since Mar 15, 2017.
FDA first approved this application on Oct 26, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-10-25 MG
olmesartan medoxomil / amlodipine besylate / hydrochlorothiazideStrength
10; 25; 40 mg/1; mg/1; mg/1
Manufacturer
Endo USA Inc.NDC
49884079011
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMILApproval Type
Generic (ANDA)
FDA Application
ANDA206137FDA Approved
10/26/2016
TE Code
AB
On Market Since
10/26/2016
Pharmacological Classes
Price Statistics
The NADAC for OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-10-25 MG has been published 499 times since Mar 15, 2017, and over the history we have for it it has declined 69.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.9895 per EA |
|---|---|
| All-time high | $3.4731 (May 10, 2017) |
| All-time low | $0.9895 (Sep 23, 2026) |
| 52-week high | $1.3916 |
| 52-week low | $0.9895 |
| Median price | $1.7221 |
| Average price | $1.8573 |
| Largest weekly change | +29.2% (Dec 23, 2020) |
| Weeks tracked | 499 |
| Tracking since | Mar 15, 2017 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Endo USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin 2 Receptor Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-10-25 MG?
The current National Average Drug Acquisition Cost (NADAC) for OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-10-25 MG, manufactured by Endo USA Inc., is $0.9895 per EA (NDC 49884079011), effective Sep 30, 2026.
How has the price of OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-10-25 MG changed over time?
Over the history we have for it, the NADAC for OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-10-25 MG has declined 69.7%. It has been tracked across 499 weekly CMS publications since Mar 15, 2017.
What are the highest and lowest recorded NADAC prices for OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-10-25 MG?
Since Mar 15, 2017, the NADAC for OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-10-25 MG has ranged from a low of $0.9895 (Sep 23, 2026) to a high of $3.4731 (May 10, 2017), with a median of $1.7221 per EA.
Are there cheaper alternatives to OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-10-25 MG?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-10-25 MG in a comparable dosage form, but none are currently priced below it.
Who manufactures OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-10-25 MG?
OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-10-25 MG (NDC 49884079011) is labeled by Endo USA Inc., and CMS classifies it as a generic product.